PMH69 Racial/Ethnic differences in the use of Complementary and Alternative Medicine in Adults with moderate Mental Distress: results from 2012 National Health Interview Survey  by Rhee, T.G. et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A127
OBJECTIVES: While some complementary and alternative medicine (CAM) modali-
ties are known to be effective in treating and/or managing anxiety and depres-
sion, relatively little is known about the patterns of CAM use among U.S. adults 
with moderate mental distress (MMD). We (1) examined whether the prevalence 
rates of CAM use varies by race/ethnicity in U.S. adults with MMD, and (2) assessed 
which socio-demographic and health-related factors are associated with CAM use 
among these racially/ethnically diverse groups. METHODS: We used data collected 
from 2012 National Health Interview Survey (NHIS), which represents non-insti-
tutionalized U.S. adults with MMD (n= 6,016 unweighted). Using a cross-sectional 
design with survey data analysis techniques, we conducted descriptive analyses for 
prevalence rates of CAM use and multivariate logistic regression analyses to predict 
CAM use. RESULTS: Among adults with MMD, the overall prevalence of past year 
CAM use was significantly different across racial/ethnic groups (P< 0.0001), with 
Asians (44.7%) and others (46.8%) having the highest prevalence rates. Blacks and 
Hispanics had prevalence rates of 24.3% and 30.7%, respectively, which were lower 
than non-Hispanic Whites (44.3%). When controlling for other relevant factors, being 
younger in age (18-64), being female, living in the West, having higher educational 
attainment, being employed, having more than four ambulatory care visits and 
functional limitations were significantly associated with higher odds of CAM use 
(P< 0.05). CONCLUSIONS: Racial/ethnic differences exist in CAM use among U.S. 
adults with MMD. We also observed factors associated with higher odds of such CAM 
use, such as age, gender, geographic location, employment status, frequent ambu-
latory care visits, and functional limitations. To improve patient-centered mental 
health care, which may include integration of CAM use, mental health professionals 
and researchers should acknowledge that racial/ethnic differences exist in CAM use. 
Further studies are needed to explore why such patterns exist, and consequently, 
affect racial/ethnic minorities’ mental health.
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OBJECTIVES: The objective of this study was to examine the impact of obesity 
on one’s physical and mental health, healthcare costs and satisfaction with their 
healthcare. We hypothesized that obese respondents would report worse physical 
and mental health, higher medical costs and poorer satisfaction with their health-
care than patients without a diagnosis of obesity. METHODS: A representative 
(U.S.) sample of 5,000 adults completed an online survey regarding their health 
and healthcare. We compared respondents who were previously diagnosed with 
obesity to those who were not. We conducted bivariate analyses and multivariate 
logistic regression to assess the relationship between obesity and the outcomes of 
interest. RESULTS: 12% (n= 609) of respondents reported having been diagnosed 
with obesity. In bivariate analysis obese respondents reported worse overall physical 
health (p< .00001) and mental health (p < .0001). Additionally, respondents with a 
diagnosis of obesity were more likely to screen positive (20.8% vs 12%) on the PHQ-2 
depression screener (p < . 05). While out of pocket costs were significantly higher 
in obese respondents (p < .05), non-obese respondents tended to report paying 
more for their health insurance premiums (p< .05). Obesity was also associated 
with having more comorbid conditions (2.7 vs 1.9 respectively; p < .0001). Levels of 
satisfaction with the health system, their healthcare plan and healthcare provider 
between the groups varied. Multivariate analyses controlling for potential confound-
ing factors, including comorbidities, as expected impacted these findings and will 
be presented. CONCLUSIONS: Obesity is a public health epidemic and contributes 
to poor health outcomes. As the U.S. healthcare delivery system moves toward 
population based health care approaches, more research among obese individuals 
is needed to better understand the association between obesity and poor outcomes 
but also the relationship with other independent predictors that can be modified 
or addressed to enhance the health of our nation.
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OBJECTIVES: Underuse of clozapine, an evidence-based practice, and overuse of 
non-clozapine antipsychotic polypharmacy (hereafter, antipsychotic polyphar-
macy), an unsupported practice to treat patients with schizophrenia may result in 
undesirable consequences. This study evaluated provider-level prevalence of clozap-
ine and antipsychotic polypharmacy prescribing and associated factors. METHODS: 
Using 2010-2012 data from Pennsylvania’s Medicaid we identified all providers who 
regularly prescribed antipsychotics to non-elderly adult patients with schizophrenia 
(defined as ≥ 10 patients/year). We characterized providers’ patients and payers 
(managed care vs. fee-for-service) using Medicaid data, and providers’ demographics 
using CMS’s NPI file. We measured provider-level share of patients with clozapine 
use and antipsychotic polypharmacy use per year. Antipsychotic polypharmacy was 
defined as more than 90 days’ concurrent use of ≥ 2 non-clozapine antipsychotics, 
with 32-day gap allowance. We used generalized estimating equations with a bino-
mial distribution and a logit link to examine clozapine and antipsychotic polyphar-
macy practices and associated patient- and provider-level factors. RESULTS: The 
analytic cohort included 632-650 prescribers per year. Provider-level clozapine and 
antipsychotic polypharmacy practices were relatively stable over time. In 2012, pro-
vider-level mean shares of patients with clozapine and antipsychotic polypharmacy 
use were 6.9% (range: 0%-88.9%) and 7.0% (range: 0%-45.2%), respectively. A sizable 
proportion of providers prescribed antipsychotic polypharmacy but not clozapine 
(e.g., 15.5% in 2012). High volume prescribers were much more likely to prescribe 
clozapine (OR = 1.43, p< 0.01) and antipsychotic polypharmacy (OR = 2.65, p< 0.01) 
matched JC and non-JC patients to evaluate effectiveness of the program is on-
going. RESULTS: A total of 102 JC patients were included (15 continuous users 
and 87 new users). The mean age was 41 years (SD=13), 63% were males, 64% 
were covered by Medicaid, or Medicare, or dually covered, 63% lived with family/
friends and 29%, 30% and 25% had comorbidity conditions of depression, anxiety 
and bipolar disorder, respectively.  In the pre-index period, 22% of JC patients had 
any use of inpatient hospitalization, emergency room (ER) or crisis stabilization 
unit (20%, 1% and 5%, respectively) and 77% had outpatient visits.  Pre-index oral 
atypical antipsychotics (73%) and antidepressants (59%) were commonly used.  In 
the post- index period, 18% of patients had any use of inpatient hospitalization, ER 
or crisis stabilization unit (15%, 2% and 3%, respectively) and 84% had outpatient 
visits. Post-index oral atypical antipsychotics and antidepressant use was 59% 
and 57%, respectively. CONCLUSIONS: Preliminary evidence shows numerically 
lower inpatient, ER and crisis unit utilization from pre- to post-index period among 
schizophrenia JC enrollees.
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OBJECTIVES: To explore medication use patterns, health-care resource utili-
zation and economic burden among patients with schizophrenia in Beijing, 
China. METHODS: A retrospective analysis was performed using the Beijing Urban 
Employee Basic Medical Insurance Database from January 1, 2011 to December 31, 
2013. Patients diagnosed with schizophrenia were identified using the International 
Classification of Disease 10th diagnosis codes F20, and the first diagnosis date in 
2012 was designated as the index date. Patients were required to be at least 18 years 
old, without any cancer and with 12-months continuous enrollment after the index 
date. Descriptive statistics were used to describe patient profiles, medication usage, 
health-care resource utilization and annual direct medical costs during the 1-year 
follow-up period. RESULTS: A total of 17,609 patients were included with mean 
(±SD) age of 52 (±15) years, 54% females and 94% with the baseline medical co-
morbidities. During the study follow-up, 75% received antipsychotic monotherapy 
and 84% were treated with atypical antipsychotics. The proportion of patients with 
schizophrenia-related hospitalization was 9.6%, with 1.2 (±0.5) hospitalizations per 
patient-year, 118 (±98) days of total length of hospitalization stay per patient-year, 
and a 21% re-admission rate. Those with any schizophrenia-related outpatient visit 
had 5.7 (±4.4) outpatient visits per patient-year, with 82% having at least 2 outpatient 
visits. The all-cause annual direct medical costs per patient were $2,668 (±3,511), 
while schizophrenia-related annual costs were $950 (±2,150). The costs per schizo-
phrenia-related hospitalization were $4,050 (±3,592), with 10% of costs attributable 
to antipsychotics and 81% to non-medication medical costs. CONCLUSIONS: In 
Beijing, patients diagnosed with schizophrenia had a low rate of schizophrenia-
related hospitalization, and a high rate of medical co-morbidities. Most patients 
received antipsychotic monotherapy and atypical antipsychotics. The economic 
burden associated with schizophrenia was considerable.
PMH68
CliniCAl AsPeCts of inteRnet AddiCtion AMong students: is it 
disoRdeR oR tRend of tHe tiMes?
Salpynov Z., Karp L., Salpynov L., Potapchyuk T., Almadiyeva A.
Astana Medical University, Astana, Kazakhstan
OBJECTIVES: To investigate Internet addiction (IA) among the students of three 
major universities: Astana Medical University (Kazakhstan), Ukrainian Medical 
Stomatological Academy (Ukraine) and Tashkent Institute of Railway Transport 
Engineers (Uzbekistan). METHODS: Our study was based on a questionnaire, which 
included two sections: demographic part and a traditional K.Yang’s questionnaire. 
Problematic Internet Use (PIU) indices were calculated according to 4 scales: social 
comfort, loneliness, distraction, and impulsiveness. We used Student’s t-test, 
Spearmen’s rank correlation coefficient and Cronbach alpha coefficient. RESULTS: 
The majority of male and female students reported about using Internet five or more 
times a week. It was detected a statistically significant difference between men and 
women according to the latter type of activity, where females were more likely to use 
the Internet for entertainment than males (p< 0.05). Data showed statistically signifi-
cant differences among men. The same comparison among women did not find any 
significant differences. IA disorder can lead to «Dry eye» syndrome, carpal tunnel 
syndrome (6,8%), neuroses, backaches and neckaches among young people. One of 
four respondents noted that they had an experienced pain, numbness in hands and 
wrists. Almost half of the students complain that they are concerned about their 
eyesight. The high value of the Spearman rank correlation coefficient (ranging from 
0.91 to 0.99) testifies about the inverse association between the number of answers 
and their rank. CONCLUSIONS: When all results were compared, statistically sig-
nificant differences of the comparative characterization of PIU among students by 
gender did not found (p> 0.05). The null hypothesis, which has proved the lack of 
differences in indicators of addictive behavior among students, is not confirmed. 
We found higher PIU indices among Kazakhstani students in the category of Social 
Comfort, in comparison with the students from Uzbekistan, having high PIU indices 
in the category of Diminished Impulse Control.
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